1,063 Matching Annotations
  1. Last 7 days
    1. Davis, H. E., Assaf, G. S., McCorkell, L., Wei, H., Low, R. J., Re’em, Y., Redfield, S., Austin, J. P., & Akrami, A. (2021). Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine, 0(0). https://doi.org/10.1016/j.eclinm.2021.101019

    2. A significant number of patients with COVID-19 experience prolonged symptoms, known as Long COVID. Few systematic studies have investigated this population, particularly in outpatient settings. Hence, relatively little is known about symptom makeup and severity, expected clinical course, impact on daily functioning, and return to baseline health.
    3. 2021-07-15

    4. 10.1016/j.eclinm.2021.101019
    5. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact
    1. Al-Aly, Z., Xie, Y., & Bowe, B. (2021). High-dimensional characterization of post-acute sequelae of COVID-19. Nature, 594(7862), 259–264. https://doi.org/10.1038/s41586-021-03553-9

    2. 10.1038/s41586-021-03553-9
    3. The acute clinical manifestations of COVID-19 have been well characterized1,2, but the post-acute sequelae of this disease have not been comprehensively described. Here we use the national healthcare databases of the US Department of Veterans Affairs to systematically and comprehensively identify 6-month incident sequelae—including diagnoses, medication use and laboratory abnormalities—in patients with COVID-19 who survived for at least 30 days after diagnosis. We show that beyond the first 30 days of illness, people with COVID-19 exhibit a higher risk of death and use of health resources. Our high-dimensional approach identifies incident sequelae in the respiratory system, as well as several other sequelae that include nervous system and neurocognitive disorders, mental health disorders, metabolic disorders, cardiovascular disorders, gastrointestinal disorders, malaise, fatigue, musculoskeletal pain and anaemia. We show increased incident use of several therapeutic agents—including pain medications (opioids and non-opioids) as well as antidepressant, anxiolytic, antihypertensive and oral hypoglycaemic agents—as well as evidence of laboratory abnormalities in several organ systems. Our analysis of an array of prespecified outcomes reveals a risk gradient that increases according to the severity of the acute COVID-19 infection (that is, whether patients were not hospitalized, hospitalized or admitted to intensive care). Our findings show that a substantial burden of health loss that spans pulmonary and several extrapulmonary organ systems is experienced by patients who survive after the acute phase of COVID-19. These results will help to inform health system planning and the development of multidisciplinary care strategies to reduce chronic health loss among individuals with COVID-19.
    4. 2021-04-22

    5. High-dimensional characterization of post-acute sequelae of COVID-19
  2. Jul 2021
    1. Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine in Pregnancy. (2021, July 12). https://doi.org/10.21203/rs.3.rs-665725/v1

    2. 2021-07-12

    3. Background: As mass vaccination campaigns against COVID-19 accelerate worldwide, there remains only limited evidence regarding vaccine effectiveness (VE) among pregnant women. Pregnant women have been shown to be at risk for severe COVID-19, resulting in adverse obstetrics outcomes, and their immune system is known to undergo alterations during pregnancy. Phase III clinical trials of the approved mRNA COVID-19 vaccines excluded pregnant women, yet current guidelines encourage offering the vaccine to pregnant women. In this study, we examine data from Israel’s largest healthcare organization to evaluate the effectiveness of the BNT162b2 mRNA vaccine among pregnant women. 
    4. 10.21203/rs.3.rs-665725/v1
    5. Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine in Pregnancy
    1. Toor, J., Echeverria-Londono, S., Li, X., Abbas, K., Carter, E. D., Clapham, H. E., Clark, A., de Villiers, M. J., Eilertson, K., Ferrari, M., Gamkrelidze, I., Hallett, T. B., Hinsley, W. R., Hogan, D., Huber, J. H., Jackson, M. L., Jean, K., Jit, M., Karachaliou, A., … Gaythorpe, K. A. (2021). Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. ELife, 10, e67635. https://doi.org/10.7554/eLife.67635

    2. Vaccination is one of the most effective public health interventions. We investigate the impact of vaccination activities for Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae, and yellow fever over the years 2000–2030 across 112 countries.
    3. 2021-07-13

    4. Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world
    1. We tested the link between COVID-19 conspiracy theories and health protective behaviours in three studies: one at the onset of the pandemic in the United Kingdom (UK), a second just before the first national lockdown, and a third during that lockdown (N = 302, 404 and 399). We focused on conspiracy theories that did not deny the existence of COVID-19 and evaluated the extent to which they predicted a range of health protective behaviours, before and after controlling for psychological and sociodemographic characteristics associated with conspiracy theory belief. COVID-19 conspiracy beliefs were positively correlated with beliefs in other unrelated conspiracies and a general conspiracy mind-set, and negatively correlated with trust in government and a tendency towards analytical thinking (vs. intuitive thinking). Unexpectedly, COVID-19 conspiracy believers adhered to basic health guidelines and advanced health protective measures as strictly as non-believers. Conspiracy believers were, however, less willing to install the contact-tracing app, get tested for and vaccinated against COVID-19, and were more likely to share COVID-19 misinformation – all of which might undermine public health initiatives. Study 3 showed conspiracy theory believers were less willing to undertake health protective behaviours that were outside of their personal control, perceiving these as having a negative balance of risks and benefits. We discuss models explaining conspiracy beliefs and health protective behaviours, and suggest practical recommendations for public health initiatives.
    2. 10.1002/ejsp.2796
    3. Are COVID-19 conspiracies a threat to public health? Psychological characteristics and health protective behaviours of believers
  3. Jun 2021
    1. Simon DeDeo and Elizabeth Hobson on equality and hierarchy | Santa Fe Institute. (n.d.). Retrieved 30 June 2021, from https://www.santafe.edu/news-center/news/simon-dedeo-and-elizabeth-hobson-equality-and-hierarchy

    2. 2021-05-18

    3. What determines the pecking order in a flock of birds? Or the page rank of a website in a Google search? Or which academics land the most prestigious jobs? Hierarchies are everywhere, and new research continues to advance our understanding of how and why some end up high and others low. As it turns out, if we look at the general patterns that emerge when hierarchies form, we can offer a single answer to each of these questions.
    4. Simon DeDeo and Elizabeth Hobson on equality and hierarchy
    1. Crotty, S. (2021). Hybrid immunity. Science, 372(6549), 1392–1393. https://doi.org/10.1126/science.abj2258

    2. Immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a vital issue for global society. Determining the quality and duration of that immunity is therefore key. But the adaptive immune system is complex, and these factors may differ between natural immunity (obtained by infection) and vaccine-generated immunity (1). Additionally, there is the question of the combination: What kind of immunity develops in people with natural immunity who are subsequently vaccinated? Such “hybrid immunity” is particularly interesting because of the notable finding that people with previous SARS-CoV-2 infection mount unusually potent immune responses to COVID-19 vaccines (2). This is exemplified in two studies in this issue on pages 1413 and 1418 by Stamatatos et al. (3) and Reynolds et al. (4), respectively, which also highlight natural and vaccine-induced immune responses to variants.
    3. 2021-06-25

    4. 10.1126/science.abj2258
    5. Hybrid immunity
    1. 2021-06-29

    2. Berger, K., Riedel-Heller, S., Pabst, A., Rietschel, M., & Richter, D. (2021). Einsamkeit während der ersten Welle der SARS-CoV-2 Pandemie—Ergebnisse der NAKO-Gesundheitsstudie. PsyArXiv. https://doi.org/10.31234/osf.io/k4efw

    3. 10.31234/osf.io/k4efw
    4. Hintergrund: Mit Beginn der SARS-CoV-2 Pandemie und der nachfolgenden Maßnahmen zu ihrer Eindämmung im Frühjahr 2020, ist rasch die Frage nach Auswirkungen einer Beschränkung sozialer Kontakte auf die psychische Gesundheit der Bevölkerung aufgekommen. Einsamkeit beschreibt die wahrgenommene Qualität der eigenen Kontakte und Beziehungen zu anderen Menschen. Zahlreiche Studien haben einen Zusammenhang von Einsamkeit mit somatischen und psychischen Erkrankungen aufgezeigt. Ziel: Auswertung der Häufigkeit von Einsamkeit und ihrer Beziehung zu Angst- und Depressionssymptomen in der ersten Welle der Pandemie im Mai 2020. Methoden: Die NAKO-Gesundheitsstudie (NAKO) hat zwischen 2014 und 2019 205.000 Personen im Alter zwischen 20 und 69 Jahren in 18 Studienzentren in Deutschland rekrutiert und untersucht. Die nachfolgende Zweituntersuchung musste auf Grund der Pandemie im Frühjahr 2020 unterbrochen werden. In dieser Zeit wurde ein COVID-19 bezogener Fragebogen entwickelt und an alle Teilnehmenden verschickt. Ausgewertet wurden die 113.928 Fragebögen, die innerhalb der ersten 30 Tage zurückgeschickt wurden. Einsamkeit wurde mit der 3-Item UCLA-Loneliness-Scale, Angst und Depression mit den PHQ-9 und GAD-7 Skalen des Patient Health Questionnaire erhoben. Ergebnisse: Im Mai 2020 nahmen sich 31,7 % der NAKO-Teilnehmenden als einsam wahr. Frauen und junge Menschen waren häufiger als Männer und ältere Personen betroffen. Mit steigender Wahrnehmung von Einsamkeit nahm der Schweregrad von Depressions- und Angstsymptomen stetig zu. Einsame Personen während der Pandemie gaben bereits zur NAKO-Basisuntersuchung mehr depressive und Angstsymptome an als NAKOTeilnehmende, die in der Pandemie nicht einsam waren. Schlussfolgerung: In der NAKO-Gesundheitsstudie zeigte sich während der ersten Phase der Pandemie ein Zuwachs an Einsamkeit und ihr deutlicher Zusammenhang mit schlechterer, psychischer Gesundheit. See less
    5. Einsamkeit während der ersten Welle der SARS-CoV-2 Pandemie - Ergebnisse der NAKO-Gesundheitsstudie
    1. Soderberg, C. K., Errington, T. M., Schiavone, S. R., Bottesini, J., Thorn, F. S., Vazire, S., Esterling, K. M., & Nosek, B. A. (2021). Initial evidence of research quality of registered reports compared with the standard publishing model. Nature Human Behaviour, 1–8. https://doi.org/10.1038/s41562-021-01142-4

    2. In registered reports (RRs), initial peer review and in-principle acceptance occur before knowing the research outcomes. This combats publication bias and distinguishes planned from unplanned research. How RRs could improve the credibility of research findings is straightforward, but there is little empirical evidence. Also, there could be unintended costs such as reducing novelty. Here, 353 researchers peer reviewed a pair of papers from 29 published RRs from psychology and neuroscience and 57 non-RR comparison papers. RRs numerically outperformed comparison papers on all 19 criteria (mean difference 0.46, scale range −4 to +4) with effects ranging from RRs being statistically indistinguishable from comparison papers in novelty (0.13, 95% credible interval [−0.24, 0.49]) and creativity (0.22, [−0.14, 0.58]) to sizeable improvements in rigour of methodology (0.99, [0.62, 1.35]) and analysis (0.97, [0.60, 1.34]) and overall paper quality (0.66, [0.30, 1.02]). RRs could improve research quality while reducing publication bias and ultimately improve the credibility of the published literature.
    3. 10.1038/s41562-021-01142-4
    4. Initial evidence of research quality of registered reports compared with the standard publishing model
    5. 2021-06-24

    1. Zou, X., & Cao, B. (2021). COVID-19 vaccines for children younger than 12 years: Are we ready? The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00384-4

    2. 2021-06-28

    3. On May 5, 2021, Canada became the first country in the world to approve COVID-19 vaccine for emergency use in children aged 12–15 years; later the same month, the US Food and Drug Administration and European Medicines Agency also gave the green light to the Pfizer-BioNTech COVID-19 vaccine for adolescents.1Centers for Disease Control and PreventionCOVID-19 vaccines for children and teens.https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/adolescents.htmlDate: 2021Date accessed: June 6, 2021Google Scholar Children younger than 12 years are the next population who need a safe and efficient COVID-19 vaccine. In The Lancet Infectious Diseases, Bihua Han and colleagues reported the results of a double-blind, randomised, controlled, phase 1/2 clinical trial, which showed that the inactivated COVID-19 vaccine (CoronaVac) had good safety, tolerability, and immunogenicity in youths aged 3–17 years.2Han B Song Y Li C et al.Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.Lancet Infect Dis. 2021; (published online June 28.)https://doi.org/10.1016/S1473-3099(21)00319-4Summary Full Text Full Text PDF Google Scholar This promising result should inspire the ongoing trial of other COVID-19 vaccines in children younger than 12 years.
    4. 10.1016/S1473-3099(21)00384-4
    5. COVID-19 vaccines for children younger than 12 years: are we ready?
    1. Thomson, M. L. P., Clare Wilson, Adam Vaughan and Helen. (n.d.). Long covid: Do I have it, how long will it last and can we treat it? New Scientist. Retrieved 28 June 2021, from https://www.newscientist.com/article/mg25033403-600-long-covid-do-i-have-it-how-long-will-it-last-and-can-we-treat-it/

    2. MORE than a million people in the UK are living with long covid, according to the UK’s Office for National Statistics (ONS). And while global figures vary, it is thought that about 14 per cent of people who catch covid-19 end up with lasting symptoms – which is some 25 million people worldwide. This could be a big underestimate, though, because less than 10 per cent of infections are thought to be detected, so the true figure could be nearer 250 million.
    3. 2021-06-23

    4. Long covid: Do I have it, how long will it last and can we treat it?
    1. Smith, A. M., Willroth, E. C., Gatchpazian, A., Shallcross, A. J., Feinberg, M., & Ford, B. Q. (2021). Coping With Health Threats: The Costs and Benefits of Managing Emotions. Psychological Science, 09567976211024260. https://doi.org/10.1177/09567976211024260

    2. How people respond to health threats can influence their own health and, when people are facing communal risks, even their community’s health. We propose that people commonly respond to health threats by managing their emotions with cognitive strategies such as reappraisal, which can reduce fear and protect mental health. However, because fear can also motivate health behaviors, reducing fear may also jeopardize health behaviors. In two diverse U.S. samples (N = 1,241) tracked across 3 months, sequential and cross-lagged panel mediation models indicated that reappraisal predicted lower fear about an ongoing health threat (COVID-19) and, in turn, better mental health but fewer recommended physical health behaviors. This trade-off was not inevitable, however: The use of reappraisal to increase socially oriented positive emotions predicted better mental health without jeopardizing physical health behaviors. Examining the costs and benefits of how people cope with health threats is essential for promoting better health outcomes for individuals and communities.
    3. 2021-06-18

    4. 10.1177/09567976211024260
    5. Coping With Health Threats: The Costs and Benefits of Managing Emotions
    1. 2021-05-21

    2. "I think the #EU needs to be on the right side of history.” @JNkengasong Head of @AfricaCDC welcomes news of $1.2 bn EU investment but says the continent can produce vaccines at scale IF #patents are waived. "The time is always right to do the right thing..." PART I
    3. Julia Chatterley. (2021, May 21). "I think the #EU needs to be on the right side of history.” @JNkengasong Head of @AfricaCDC welcomes news of $1.2 bn EU investment but says the continent can produce vaccines at scale IF #patents are waived. ‘The time is always right to do the right thing...’ PART I https://t.co/N1Xw9QLFhu [Tweet]. @jchatterleyCNN. https://twitter.com/jchatterleyCNN/status/1395755122320416775

    1. Coronavirus and vaccination rates in people aged 70 years and over by socio-demographic characteristic, England—Office for National Statistics. (n.d.). Retrieved 27 June 2021, from https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthinequalities/bulletins/coronavirusandvaccinationratesinpeopleaged70yearsandoverbysociodemographiccharacteristicengland/8december2020to11march2021

    2. 2021-03-29

    3. First dose COVID-19 vaccination rates among people aged 70 years and older who live in England, both in private households and communal establishments. Includes estimates for the population as a whole by age and sex, and for ethnic minorities, religious groups, those identified as disabled and by area deprivation.